Although drugs that target the inhibition of the action of VWF have not yet reached approval for the market (17), studies on FVIII/VWF levels during stroke and thrombolysis might provide useful descriptive data to understand the pathophysiology relevant to the potential clinical application of these inhibitors in the future in humans. This evidence concerns the gene F8 and Stroke.